{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:08:26Z","timestamp":1790284106448,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.autrev.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:19:09Z","timestamp":1467796749000},"page":"931-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Systemic-onset juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"15","author":[{"given":"Rolando","family":"Cimaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.07.004_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaut.2015.08.002","article-title":"Immunogenetics of juvenile idiopathic arthritis: a comprehensive review","volume":"64","author":"Hersh","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2016.07.004_bb0010","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2015.04.007","article-title":"Juvenile idiopathic arthritis and physical activity: possible inflammatory and immune modulation and tracks for interventions in young populations","volume":"14","author":"Rochette","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.07.004_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2014.01.009","article-title":"Diagnosis and classification of juvenile idiopathic arthritis","volume":"48\u201349","author":"Eisenstein","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2016.07.004_bb0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review","volume":"81","author":"Thierry","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2016.07.004_bb0030","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2016.07.004_bb0035","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1084\/jem.20070070","article-title":"Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade","volume":"204","author":"Allantaz","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2016.07.004_bb0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/art.38877","article-title":"Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis","volume":"67","author":"Wakil","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0045","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1073\/pnas.1520779112","article-title":"HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis","volume":"112","author":"Ombrello","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.07.004_bb0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","volume":"65","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2016.07.004_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/j.ajkd.2011.11.002","article-title":"ANCA-associated glomerulonephritis in systemic-onset juvenile idiopathic arthritis","volume":"59","author":"Belot","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2016.07.004_bb0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/art.24349","article-title":"The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1 beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"Frosch","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.004_bb0065","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0070","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/art.38769","article-title":"Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"66","author":"Davi","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0075","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0080","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"de Jager","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.004_bb0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2016.07.004_bb0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2016.07.004_bb0095","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2016.07.004_bb0100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.07.004_bb0105","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.004_bb0110","first-page":"203","article-title":"Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?","volume":"25","author":"De Benedetti","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0115","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.004_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.07.004_bb0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.004_bb0130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0135","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.004_bb0140","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2016.07.004_bb0145","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.004_bb0150","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.004_bb0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2016.07.004_bb0160","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2016.07.004_bb0165","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1002\/art.38875","article-title":"REACCH OUT and BBOP Research Consortia, The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis","volume":"66","author":"Eng","year":"2014","journal-title":"Arthritis Rheumatol."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:50:52Z","timestamp":1718682652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216301392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1568997216301392"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic-onset juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}